[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2008045766A2 - Procédé pour le traitement de la peau - Google Patents

Procédé pour le traitement de la peau Download PDF

Info

Publication number
WO2008045766A2
WO2008045766A2 PCT/US2007/080501 US2007080501W WO2008045766A2 WO 2008045766 A2 WO2008045766 A2 WO 2008045766A2 US 2007080501 W US2007080501 W US 2007080501W WO 2008045766 A2 WO2008045766 A2 WO 2008045766A2
Authority
WO
WIPO (PCT)
Prior art keywords
skin
peptide
solution
method further
receptor
Prior art date
Application number
PCT/US2007/080501
Other languages
English (en)
Other versions
WO2008045766A3 (fr
Inventor
Liliane Sallander
Original Assignee
True Look Skin Care Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by True Look Skin Care Inc. filed Critical True Look Skin Care Inc.
Priority to US12/444,686 priority Critical patent/US20100021401A1/en
Publication of WO2008045766A2 publication Critical patent/WO2008045766A2/fr
Publication of WO2008045766A3 publication Critical patent/WO2008045766A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Definitions

  • the present invention relates to a method for treating skin. More particularly, the method is for treating the skin with a suitable amino acid such as a peptide compound.
  • the skin is composed of connective tissues.
  • the skin also contains different cell types such as keratinocytes, melanocytes, fibroplast and Langerhans.
  • the connective tissues are rich in extra cellular matrices (ECM) that are composed of four major groups including two fibrous molecules such as collagen and elastin and two glycoconjugates including glycoproteins and glycans, such as proteoglycans, glycosaminoglycans .
  • ECM extra cellular matrices
  • Collagen is a protein that accounts for about 70% of the extra cellular matrix.
  • Elastin only accounts for about 1-3% but is very important.
  • Glycoproteins such as fibronectin and laminin are involved in the matrix components.
  • the dermal fibroplasts coordinate the biosynthesis of all the components of the extra cellular matrix.
  • the aging effects on the extra cellular matrix include the loss of cells and ECM substance, undesirable modification of the skin thickness and the matrix composition.
  • the aging of the skin also results in the loss of elastin that reduces the skin elasticity. There is also a loss of hydration due to loss of glycosaminoglycans.
  • the method of the present invention provides a solution to the above-mentioned problems and drawbacks. More particularly, the method of the present invention is for treating skin.
  • a peptide is selected that affects a receptor so that the receptor is receptive to the peptide.
  • the selected peptide is dissolved in a solution to form a peptide solution.
  • the skin is vibrated to generate heat without reducing the peptide in the peptide solution.
  • the peptide solution is applied to the skin.
  • the peptide solution increases an operational activity of the receptor in the skin.
  • Fig. 1 is a schematic cross-section of a skin segment
  • Fig. 2 is a schematic illustration showing receptors and the interaction between peptides and receptors.
  • An important aspect of the method of the present invention is that a suitable peptide is selected depending upon which receptor should be affected or stimulated. By changing the type of peptide used, different receptors will be affected. Another important and surprising discovery of the present invention is that the method pin-points exactly the parts of the skin that should be treated and preserved because short- chain amino acids, such as peptides, act only upon specific receptors, which in turn narrows down the natural reaction. To obtain the optimal effect it is of outmost importance to balance the peptides in specific and accurate compositions that affect the correct receptors and improve the overall skin.
  • a surprising discovery is that tripeptides act upon and stimulate the elastin receptors together with melibiose and fucose-mannose catalysts disposed on the cell membranes and the added oligosaccharides (fucose) acts even upon the cell membranes.
  • Peptides are made of short chains of amino acids which are in different from proteins that have long chains of amino acids. In the body, peptides regulate the activity of other molecules such as proteins. This regulation is achieved by the interaction of the peptide with the target molecule i.e. the molecule to be treated. Peptides have many functions and some can have hormonal activity and other antibiotic functions.
  • the dermis contains fibroplasts which synthesize an interstitial tissue such as ECM that is composed of several compounds.
  • ECM includes collagen, with two main proteins (I & III) which make up the system of fibers that gives the skin its strength. It also includes elastin, a protein fiber with a molecular structure that allows for stretching and tension, and makes the skin supple.
  • ECM further includes laminin, a binding protein located at the junction of the dermis and epidermis, which acts in the interaction of the cell/matrix. It also includes fibronectin, which belongs to the same category and is involved in the healing and homeostasis of the skin. Deterioration of the mechanical properties of ageing skin is a consequence of ECM atrophy. In order to prevent premature ageing of the skin it is of outmost importance to maintain the integrity of its matrix.
  • peptides may be used to repair skin defects. More particularly, it was surprisingly discovered that a cream that contains tripeptide-1 participates in tissue repair and restarts extra cellular matrix renewal. Fibroplastine contributes to the repair of micro-injuries to the skin. It regenerates the skin that has been damaged from normal ageing or the environment due to damage to the dermis.
  • peptide could be combined with a suitable natural yeast/sugar substance to further reduce the degradation process.
  • An important feature of the method of the present invention is to directly affect the receptors.
  • Integrins are specific receptors that affect the aging process of the skin. Elastic receptor with laminin receptors may be directly disturbed due to age-related factors and therefore release more damaging free radicals. This leads to a degradation of elastin. Additionally, fibronectin degradation is directly linked to elastin degradation.
  • oligosaccharides that may be derived from a yeast such as saccharomyces cerevisiae and fucose-mannose, may be used to reduce or even prevent the degradation of fibronectine .
  • the composition also induces the syntheses of collagen protein and the production of fibronectin that in turn produces elastin.
  • the composition also induces the production of laminin which is an amino acid that builds up fibronectin .
  • the oligosaccharides solution is mainly used because it protects and strengthens the cell membrane that in turn protects the receptors that are located at and around the cell membrane. When the cell membrane is damaged then the receptors are often damaged too.
  • the user may see an improvement of the skin in just a couple of days. It may be possible to use from about 0.1 ppm tripeptide-1 to up to about 20 ppm tripeptide-1. Preferably, about 7-13 ppm tripeptide-1 should be used. It may also be possible to use 1% oligosaccharides and up to 30% oligosaccharides solution. Preferably, between about 5-15% of oligosaccharides solution should be used.
  • a peptide composition of the present invention may also be used for protecting the skin against discoloration and from harmful sun light.
  • Melanin is a pigment that gives the color of the skin. The amount of melanin produced is the basis of the skin pigmentation.
  • Melanocytes are the cells that are producing melanin and are located at the basal layer of the skin.
  • Melanotropin (or alpha-MSH) is the hormone that stimulates the melanocytes to produce melanin.
  • the main purpose of melanin is to protect the skin from the dangers of UVA/UVB.
  • the melanin pigment is the most natural protection of the skin.
  • the natural color of the skin is the indication of the level of the skin's own natural defense and depends upon the type of melanin, eumelanin or phaeomelanin and the quantity of melanin that exists in the skin.
  • Melanin is the substance that has the broadest UV spectrum and, both by its own action and during its synthesis, it consumes free radicals presented in the cells.
  • Melanin is synthesized from one amino acid called tyrosine. It is then oxidized to DOPA (DihydrOxy-Phenyl- Alanine) and then to Dopaquinone due to the action of a specific enzyme called tyrosinase. In this way, two different melanin substances may be produced. Melanin is synthesized inside the melanosomes located inside the melanocytes.
  • DOPA DihydrOxy-Phenyl- Alanine
  • the melanosomes are transported into the keratinocytes (skin cells) where melanin is delivered directly inside the skin cells. While inside the skin cells the melanin may be totally degraded in some humans such as white and red haired humans. These complex syntheses may not only explain the mechanism of photo protection but also the process related to age spots or brown spots. When hyperactivity of melanocytes occurs, melanin production becomes out of control. This may be due to overexposure to sun, age, genetic factors, etc. The results are increased skin pigmentation in some part of the skin and remain the same in other parts of the skin due to malfunctioning of the proper natural degradation. Therefore, age spots or brown spots are visible.
  • a solution of 0.05 mg/ml of acetyl hexapeptide-1 blended into O.lmg/ml beta-carotene solution is the base on a sun protection cream of the present invention.
  • the acetyl hexapeptide-1 ensures that the right amount of melanin is produced so that not too much melanin is produced that creates dark spots. It also prevents too little melanin from being produced in the skin which is harmful due to reduced protection against sun light.
  • the above composition is based upon the acetyl hexapeptide-1 which is a biomimetic peptide. When this peptide is applied topically it stimulates melanogenesis but does not have an overall systemic effect.
  • the composition also acts on the melanocyte by stimulating the MC-Ir receptor and inducing endocellular synthesis of tyrosinase. Langerhatine raises the level of permanent protection against UV. Its natural stimulation action on melanogenesis makes the composition the ideal sun preparation product and suntan prolonging care.
  • peptides may also be used to treat spots on the skin. Sun exposure without protection will inevitably produce brown spots or age spots on the skin. These spots are named lentigines and increase in number with age. This phenomenon is explained as a result of a hyper activity of the melanocytes that abnormally synthesize melanin.
  • the melanotropine (alpha-MSH) biological factor of melanogenese stimulation acts by reacting upon a specific receptor located on the surface of the melanocyte.
  • the peptide nonapeptide-1 used is an antagonist biomimetic reverse peptide which blocks the alpha-MSH and its effects. Moreover, by acting only upon a receptor located only on the membrane of the cell, melanosine does not influence any cell activity thus its physiological function.
  • the ECM is the interstitial tissue that connects the cells and structures the skin.
  • the dermis In the dermis, it is composed of collagen fibers associated with elastin fibers and this combination gives the skin its strength and suppleness.
  • actinic ageing one of the effects of which is elastosis or flabbiness. This is characterized by an accumulation of degraded elastin in the dermis .
  • the enzymes responsible for this breakdown are proteases, often metallo-proteases . These include elastases, the cellular production of which is strongly increased by exposure to solar radiation. It was surprisingly discovered that peptides may also be used to reduce the elastosis. More particularly, the peptide trifluoracetyl tripeptide-2 is a biomimetic peptide that inhibits elastases with a great accuracy. By inhibiting the breakdown of elastin and cutaneous proteins, keratosine efficiently combats the premature ageing of the skin and balance the adverse effects of sun exposure.
  • the skin forms it s own protective barrier than can be disturbed due to the use of inappropriate skin care products.
  • This barrier is located primarily in the outmost dermis layer.
  • the dermis is built with skin cells called keratinocytes . Not only do these cells protect the skin but they are also of utmost important as a communication link with the underlying epidermis where among other things the immune cells, such as Langerhans cells, are located. Therefore, the healthy keratinocytes are basic for a healthy young looking skin.
  • Keratinocytes also have the ability to glue together the dermis to the epidermis . From the age of about thirty, our keratinocytes start losing their ability to stick to the dermo- epidermal junction. The degradation of keratinocytes leads to a weakening of this characteristic. This is one of the factors that communications between the dermis and epidermis do not function optimally. As a result, the skin looses its firmness and become grayish since the cells lose contact with blood capillaries that nourish them. Therefore, age factors and sun exposure are slowing down the renewal effectiveness of keratinocytes that leads to a degradation of the skin appearance.
  • keratinocytes produce keratins, the mechanical properties of which provide the skin' s first physical barrier.
  • these same cells also condition the environmental balance of the other components of the epidermis, including
  • acetyl tetra ⁇ eptide-2 acts directly upon the cytokine of the keratinocytes.
  • An effective composition is acetyl tetrapeptide-2 at a concentration of 0.01 mg/ml of serilesine and a solution of synthetic hexa-peptide from laminin at a concentration of 0.05 mg/ml are blended into a cream to repair age degradation of the skin.
  • Serilesine is included in laminin amino acids that are used for building cells. The acetyl tetrapeptide-2 regulates the cytokine hormone secretion so that the cell building is indirectly affected by affecting the hormones of the cell.
  • the cytokine is a growth hormone that not only stimulates keratinocytes but also Langerhans cells. Because the cytokine hormone affects the production of Langerhans cells, it is useful as a day cream when the skin needs a good immune system the most. In this way, both the production of the immune cells and the cell building are stimulated at the same time.
  • the peptide, acetyl tetra ⁇ eptide-2 ⁇ is a biomimetic of the cell maturation factors produced by the thymus. Oxytosine acts topically on the keratinocytes, inducing endocellular synthesis of paracrine and autocrone mediators.
  • Oxytosine then stimulates the production of GM-CSF (Granulocyte Macrophage- Colony Stimulating Factor) by the keratinocytes.
  • GM-CSF Gramulocyte Macrophage- Colony Stimulating Factor
  • This cytokine stimulates not only keratinocytes renewal but also Langerhans cell maturation and improves the epidermis profile and stimulates the skin immune system.
  • the peptide system of the present invention may also be used on the skin around the eyes.
  • the skin around the eyes is very delicate. It is the thinnest area of the body. This is also where the first lines appear. Furthermore, poor blood circulation in this area results in poor skin condition caused by less intake of oxygen. Adding UV exposure further leads to wrinkles and puffiness. To reverse these factors, an eye cream should have a primary function of awakening the natural microcirculation and provide a renewal in oxygenation of the particular area without irritating the area.
  • lymphocyte activating peptide (Cas 120484-65-3) blended into a solution of 5% hydrolyzed rice bran protein glycine soy (soybean) protein oxido-reductase is very effective.
  • One important function of the lymph substances is to discharge waste products from the skin. When the lymph substances are not functioning well it is common to swell and get puffy eyes. The stimulation of the lymph flow is therefor desirable. The lymphocyte activating peptide provides this stimulation.
  • the soybean refines, softens and opens up the lymph passages and capillaries to make it easier for the lymph to flow in the skin area around the eyes.
  • lymphocyte activating peptide is preferably used in the above-described soy bean solution of between 3-10%.
  • the method use of applying the peptide on the skin is important. On a perfectly cleansed skin, a small amount of the peptide composition is applied. The composition is upwardly vibrated m order to induce the peptides into the skin. The vibrations are very important due to the fact that vibrations produce a slight heating reaction and allow the peptides to quickly penetrate into the skin without being reduced. Peptides are often very active and sometimes volatile and should be applied right away to maintain the effectiveness.
  • vibrations are generating a slight decollation or transverse movement of the epidermis that is necessary m order to preserve the proper quality of the peptides when applied. It is undesirable to apply a pressure on the skin to deform the skin because that makes the penetration of the peptides more difficult. The entire procedure of application should not last more than a few seconds .
  • light tapping on the skin is used to apply the peptide-based eye cream. Under no circumstances should usual massage be used m order to apply the products since this deforms the skin and does not induce the proper penetration process .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne un procédé pour le traitement de la peau. Un peptide est sélectionné, ledit peptide affectant un récepteur de manière à ce que le récepteur soit réceptif au peptide. Le peptide sélectionné est dissous dans une solution pour former une solution de peptide. La peau est mise en vibration afin de générer de la chaleur sans réduire le peptide dans la solution de peptide. La solution de peptide est appliquée à la peau. La solution de peptide accroît une activité opérationnelle du récepteur dans la peau.
PCT/US2007/080501 2006-10-10 2007-10-05 Procédé pour le traitement de la peau WO2008045766A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/444,686 US20100021401A1 (en) 2006-10-10 2007-10-05 Method for treating skin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82226606P 2006-10-10 2006-10-10
US60/822,266 2006-10-10

Publications (2)

Publication Number Publication Date
WO2008045766A2 true WO2008045766A2 (fr) 2008-04-17
WO2008045766A3 WO2008045766A3 (fr) 2008-12-18

Family

ID=39283523

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/080501 WO2008045766A2 (fr) 2006-10-10 2007-10-05 Procédé pour le traitement de la peau

Country Status (2)

Country Link
US (1) US20100021401A1 (fr)
WO (1) WO2008045766A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356540B (es) 2011-05-10 2018-06-01 Mary Kay Inc Composiciones cosmeticas.
AU2017215476B2 (en) 2016-02-04 2022-12-08 ALASTIN Skincare, Inc. Compositions and methods for invasive and non-invasive procedural skincare
BR112020002222A2 (pt) * 2017-08-03 2020-07-28 ALASTIN Skincare, Inc. composições e métodos para melhora da flacidez da pele e do contorno corporal
US11103455B2 (en) 2018-08-02 2021-08-31 ALASTIN Skincare, Inc. Liposomal compositions and methods of use
CN112121145A (zh) * 2020-10-28 2020-12-25 广州赛莱拉生物基因工程有限公司 三氟乙酰基三肽-2的用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040147443A1 (en) * 2002-11-13 2004-07-29 Beatrice Renault Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat winkles and fine lines
US20050063932A1 (en) * 2003-08-14 2005-03-24 Natalie Dilallo Skin care compositions including hexapeptide complexes and methods of their manufacture
US20060045896A1 (en) * 2004-08-31 2006-03-02 Tracie Martyn International, Llc Topical compositions comprising benfotiamine and pyridoxamine
US20060165643A1 (en) * 2002-07-30 2006-07-27 Karl Lintner Cosmetic or dermopharmaceutical compositions containing kombucha
US20060198800A1 (en) * 2003-08-14 2006-09-07 Natalie Dilallo Skin care compositions including hexapeptide complexes and methods of their manufacture
US20060216251A1 (en) * 2005-03-24 2006-09-28 Tracie Martyn International, Llc Topical formulations and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105288581A (zh) * 2006-06-01 2016-02-03 治疗剂肽有限公司 聚合生物表面活性剂

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165643A1 (en) * 2002-07-30 2006-07-27 Karl Lintner Cosmetic or dermopharmaceutical compositions containing kombucha
US20040147443A1 (en) * 2002-11-13 2004-07-29 Beatrice Renault Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat winkles and fine lines
US20050063932A1 (en) * 2003-08-14 2005-03-24 Natalie Dilallo Skin care compositions including hexapeptide complexes and methods of their manufacture
US20060198800A1 (en) * 2003-08-14 2006-09-07 Natalie Dilallo Skin care compositions including hexapeptide complexes and methods of their manufacture
US20060045896A1 (en) * 2004-08-31 2006-03-02 Tracie Martyn International, Llc Topical compositions comprising benfotiamine and pyridoxamine
US20060216251A1 (en) * 2005-03-24 2006-09-28 Tracie Martyn International, Llc Topical formulations and methods of use

Also Published As

Publication number Publication date
WO2008045766A3 (fr) 2008-12-18
US20100021401A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
CN109998938B (zh) 一种用于美白亮肤淡斑的多肽组合物
CN102317307B (zh) 用于治疗和/或护理皮肤、粘膜和/或头皮的肽及它们在美容组合物或药物组合物中的用途
US9458197B2 (en) Elastin digest compositions and methods utilizing same
US6620419B1 (en) Cosmetic or dermopharmaceutical use of peptides for healing, hydrating and improving skin appearance during natural or induced ageing (heliodermia, pollution)
CN103209678B (zh) 用于改进人类皮肤、毛发和/或指甲的健康的胶原蛋白水解物
CN108852894A (zh) 一种用于修复美白祛皱的多肽组合
US20100021401A1 (en) Method for treating skin
KR100721144B1 (ko) 펩타이드 혼합물을 포함하는 주름개선용 화장료 조성물
KR20120099550A (ko) 줄기세포 증식 촉진 기능을 갖는 피부 미백용 펩타이드 조성물
CN110538093A (zh) 一种多肽修复液及其制备方法
EP3773460B1 (fr) Utilisation d'un peptide pour le traitement de l'épiderme
KR101697152B1 (ko) 장어로부터 추출한 뮤신을 이용한 항노화 기능을 가지는 화장품 제재의 제조방법
CN111888279B (zh) 一种促进胶原蛋白生产的方法以及相应的药物或化妆品
CN114836488B (zh) 一种含多肽的抗皱修复组合物及其制备方法
CH696838A5 (it) Composizione cosmetica ad effetto lifting per sostenere tessuti cutanei rilassati.
CN111961119B (zh) 多肽在制备促进胶原蛋白分泌的药物或化妆品中的用途
KR20010037997A (ko) 강낭콩 추출물 및 이를 함유하는 화장료 조성물
KR101837960B1 (ko) 연근 추출물, 및 버드나무추출물 또는 프로폴리스를 함유하는 주름개선 조성물
CN116999378A (zh) 一种含有超活珍珠多肽母液的紧致亮肤组合物及其制备方法
EP1786386B1 (fr) Utilisation cosmétique, non-thérapeutique, d'au moins un tétrapeptide naturel Ac-N-Ser-Asp-Lys-Pro ou un de ses sels en tant qu'agent antiviellissement et restructurant de la peau
WO2013188774A2 (fr) Formulations de soin de la peau comprenant des complexes octapeptidiques et procédés pour les fabriquer
CN115350113A (zh) 一种含胜肽的组合物及其应用
KR102561291B1 (ko) 피부 투과성을 향상시킨 시그널 펜타펩타이드를 포함하는 피부 미백 및 주름 개선용 화장료 조성물 및 이의 제조방법
KR101729544B1 (ko) 희첨 추출물 및 동릉초 추출물을 함유하는 피부 투명도 증진용 및 피부 미백용 화장료 조성물
KR102702839B1 (ko) 피부 미백 및 주름방지 효과가 증진된 식물성 오일을 함유하는 기능성 화장품 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07843879

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12444686

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 07843879

Country of ref document: EP

Kind code of ref document: A2